NanoBio Corporation, a biopharmaceutical company focused on developing and commercializing intranasal and intramuscular vaccines, today announced that its intranasal nanoemulsion (NE) adjuvanted chlamydia vaccine has demonstrated efficacy in a traditional mouse challenge model. The study was conducted by leading chlamydia vaccine researchers at the Queensland University of Technology (QUT) in Brisbane, Australia led by Dr. Kenneth Beagley, Professor of Immunology.
